The Science Behind HelioLiver
HelioLiver LDT combines cfDNA methylation, protein biomarkers, and clinical data to support early HCC detection in high-risk patients.
Three Signals, One Clear Result
HelioLiver LDT brings together three different types of information from a single blood draw, then interprets them together to assess the likelihood of hepatocellular carcinoma in high-risk patients.
cfDNA methylation
Reads cancer-related DNA methylation changes circulating in the blood — the molecular signals that can appear before symptoms.
Protein biomarkers
Adds a second, independent layer of signal that strengthens the overall assessment alongside the methylation data.
Clinical data
Brings both biological signals together with clinical context for a clear, actionable result in high-risk patients.
Why Methylation Matters for Early Detection
Cancer cells can create detectable methylation changes in the blood — often before a tumour is large enough to be seen on imaging. By reading these changes, HelioLiver LDT is designed to identify hepatocellular carcinoma at an earlier, more treatable stage, particularly the small, early-stage lesions that are hardest to catch with ultrasound.
Detect before it's visible. Methylation signals can appear before a tumour is large enough to be seen on imaging — opening a window for earlier, more treatable intervention.
Validated in the CLiMB Trial
HelioLiver LDT was validated in the CLiMB trial — a prospective, blinded, multicenter US study in patients at high risk of HCC due to cirrhosis. Published in the Journal of Hepatology, May 2026.
High-risk population
Studied in high-risk cirrhotic patients — the population that most needs reliable HCC surveillance.
Head-to-head with ultrasound
Compared directly against ultrasound, the current standard of care, detecting Stage I HCC at 44% vs 11%.
MRI-confirmed
HCC status was confirmed by MRI in clinical evaluation, anchoring the trial's results to a clinical reference standard.
Published clinical evidence
Published in the Journal of Hepatology, May 2026 — peer-reviewed, prospective, blinded, and multicenter.
From Blood Draw to Clinical Result
A single blood draw moves through extraction, molecular analysis, and AI-based interpretation to deliver one clear result.
Blood Sample Collection
cfDNA Extraction
Methylation Analysis
Protein Biomarker Assessment
Clinical Data Integration
AI-Based Interpretation
Clinical Result
Go Deeper
Explore the platform technology behind HelioLiver, or review the full body of clinical research and trials supporting Helio's work in early cancer detection.
Explore the Technology
See the proprietary ECLIPSE™ platform and the multi-omics science that powers HelioLiver.
Explore the TechnologyRead the Research
Review the full body of clinical research and trials supporting Helio's work in early cancer detection.
Read the ResearchWhy HelioLiver Is Different
Multi-Analyte Testing
Combines cfDNA methylation, protein biomarkers, and clinical data into one assessment.
Early Detection
Designed to identify HCC at an earlier, more treatable stage — including small lesions.
Precision Oncology
Built on proprietary, patented methylation science developed over nearly a decade.
Blood-Based Testing
A single blood draw — no imaging required to generate the result.
Clinically Validated
Validated in the CLiMB trial and published in the Journal of Hepatology.
Designed for High-Risk Patients
Built for cirrhotic and other high-risk patients who most need HCC surveillance.
Bring Earlier Detection to Your Patients
HelioLiver LDT gives physicians a simple, validated way to detect liver cancer earlier — from a single blood draw.